Navigation Links
Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update
Date:3/16/2009

50 percent were achieved in 78 percent of evaluable patients who received the picoplatin combination. In addition, interim analysis revealed that the median time to PSA progression was 8.5 months with the picoplatin combination. In this study, patients were treated with picoplatin therapy for up to 10 cycles and up to a picoplatin cumulative dose of 1200 mg. Safety results continued to demonstrate that picoplatin can be safely administered with full doses of docetaxel and prednisone, the standard treatment for metastatic CRPC, supporting the use of this combination in future clinical trials.

  • Colorectal Cancer: In January 2009, the Company presented interim efficacy and safety data from its ongoing, randomized, controlled Phase 2 clinical trial of picoplatin in combination with 5-fluorouracil and leucovorin (FOLPI) in patients with metastatic colorectal cancer (CRC) at the ASCO 2009 Gastrointestinal Cancers Symposium. Results continued to show that picoplatin, given once every four weeks in the FOLPI regimen, was associated with less frequent and less severe neurotoxicity than the FOLFOX (5-fluorouracil, leucovorin and oxaliplatin) regimen, where oxaliplatin has shown treatment-limiting neurotoxicity. Results also continue to indicate that both FOLPI and FOLFOX regimens have similar anti-tumor activity as a first-line treatment for metastatic CRC, supporting the potential use of picoplatin as a neuropathy-sparing alternative to oxaliplatin.

  • Oral Picoplatin: In November, the Company announced top-line results from a Phase 1 clinical trial of an oral formulation of picoplatin in patients with solid tumors. These results indicated that picoplatin achieves linear and dose-dependent plasma exposure when given by the oral route, indicating sufficient bioavailability to support further clinical development of an oral formulation of the drug.
    '/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
2. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
5. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
6. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
7. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
8. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
9. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
10. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
11. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... Aug. 4, 2015  Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: ... epigenetic drivers of cancer, will be presenting at the 2015 ... 1:55 p.m. ET (10:55 a.m. PT) in New ... president and CEO of Mirati, will provide a corporate overview. ... be accessible on the "Investors" page of Mirati,s corporate website ...
(Date:8/4/2015)... , Aug. 4, 2015  Ironshore Pharmaceuticals ... with Restore Health, a company specializing in personalized ... double-blind clinical trial, designed to evaluate the safety ... development to treat Attention-deficit/hyperactivity disorder (ADHD). This is ... Restore Health originally partnered with Ironshore in ...
(Date:8/3/2015)... Corporation (NASDAQ: LMNX ) today announced financial results ... and operating highlights for the quarter include the following: ... 6 percent to $58.9 million, over the second quarter ... revenue by 22 percent to $24.2 million over results ... Q2 2015 royalty revenue by 17 percent to $11.1 ...
Breaking Medicine Technology:Mirati Therapeutics To Present At The 2015 Wedbush PacGrow Healthcare Conference 2Mirati Therapeutics To Present At The 2015 Wedbush PacGrow Healthcare Conference 3Restore Health Secures Another Clinical Trial with Ironshore Pharmaceuticals & Development 2Luminex Corporation Reports Record 2nd Quarter 2015 Results 2Luminex Corporation Reports Record 2nd Quarter 2015 Results 3Luminex Corporation Reports Record 2nd Quarter 2015 Results 4Luminex Corporation Reports Record 2nd Quarter 2015 Results 5Luminex Corporation Reports Record 2nd Quarter 2015 Results 6Luminex Corporation Reports Record 2nd Quarter 2015 Results 7Luminex Corporation Reports Record 2nd Quarter 2015 Results 8Luminex Corporation Reports Record 2nd Quarter 2015 Results 9Luminex Corporation Reports Record 2nd Quarter 2015 Results 10Luminex Corporation Reports Record 2nd Quarter 2015 Results 11Luminex Corporation Reports Record 2nd Quarter 2015 Results 12Luminex Corporation Reports Record 2nd Quarter 2015 Results 13Luminex Corporation Reports Record 2nd Quarter 2015 Results 14Luminex Corporation Reports Record 2nd Quarter 2015 Results 15Luminex Corporation Reports Record 2nd Quarter 2015 Results 16
... ANNAPOLIS, Md. and FAYETTEVILLE, Ark., April 4, 2012 ... provider SOAPware, Inc. have forged a strategic ... care practices transition from paper-based records to ... (EHR/EMR) systems. Together, the companies will work ...
... Texas Instruments Incorporated (TI) (NASDAQ: TXN ) ... family with five new fully integrated AFEs for portable ... (EEG) AFEs are the first to offer 16- and ... cut power consumption by more than 94 percent compared ...
Cached Medicine Technology:Syndicus, Inc. Scientific Services, SOAPware Announce Strategic Alliance 2TI introduces industry's first single- and dual-channel, 16- and 24-bit ECG/EEG analog front ends 2TI introduces industry's first single- and dual-channel, 16- and 24-bit ECG/EEG analog front ends 3TI introduces industry's first single- and dual-channel, 16- and 24-bit ECG/EEG analog front ends 4TI introduces industry's first single- and dual-channel, 16- and 24-bit ECG/EEG analog front ends 5
(Date:8/4/2015)... ... 04, 2015 , ... Oriental Trading Company, Inc., the nation’s ... school supplies, has developed engaging and affordable teacher supplies based on the beloved ... rewards, classroom decorations, crafts and educational resources featuring Carle’s vibrant illustrations and inspirational ...
(Date:8/4/2015)... ... August 04, 2015 , ... More than 700 years of marital ... vows on Friday, July 24th. Chaplains Shawn Kafader and Richard Oas lead the ... Following the ceremony was a reception, with music by the Moonlight Serenade Orchestra and ...
(Date:8/4/2015)... ... August 04, 2015 , ... Loyola University ... that its RN to BSN and Master of Science in Nursing in ... June 2020 from the Commission on Collegiate Nursing Education (CCNE), the ...
(Date:8/4/2015)... ... 04, 2015 , ... Lightning Labels is pleased to announce ... will usher in a new standard of sticker and label-making for the company. ... its twin objectives of quality and quantity without compromising the signature lightning-fast speed ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... ... their partnership to make the Isabel Symptom Checker available to all users of ... a mechanism to check their symptoms in an easy, intuitive method, provides access ...
Breaking Medicine News(10 mins):Health News:Oriental Trading Company Brings The World of Eric Carle Characters to Educators Through Classroom Supplies 2Health News:Oriental Trading Company Brings The World of Eric Carle Characters to Educators Through Classroom Supplies 3Health News:Couples Renew Vows at Friendship Village of Schaumburg 2Health News:Loyola University New Orleans Awarded Accreditation for its Online RN to BSN and MSN Programs 2Health News:Loyola University New Orleans Awarded Accreditation for its Online RN to BSN and MSN Programs 3Health News:Loyola University New Orleans Awarded Accreditation for its Online RN to BSN and MSN Programs 4Health News:Lightning Labels Installs State-of-the-Art Digital Press 2Health News:Lightning Labels Installs State-of-the-Art Digital Press 3Health News:Isabel Healthcare Partners with the Kansas Health Information Network, Inc. to Deploy Isabel Symptom Checker within the MyKSHealth eRecord Personal Health Record 2Health News:Isabel Healthcare Partners with the Kansas Health Information Network, Inc. to Deploy Isabel Symptom Checker within the MyKSHealth eRecord Personal Health Record 3
... FRANKLIN LAKES, N.J., Jan. 16 BD (Becton,Dickinson and ... company,announced today that it will host a live webcast ... 2008, at 1 p.m. (ET)., The webcast can ... and will be available for replay through Tuesday,February ...
... Agreement Provides for Provider Services, Inc. to fund $600,000 for Product, ... Millennium pursuant to the terms of the $20,000,000 5-year Purchase ... ... N.J., Jan. 16 Millennium Biotechnologies,Inc., wholly owned subsidiary of Millennium ...
... STERIS Corporation,(NYSE: STE ) today announced that ... release before the market opens on January 30, ... Eastern time. The conference,call can be heard live ... via phone,by dialing 1-888-392-9976 in the United States ...
... 16 OMI Medical Imaging, Inc. (OMI),announced today that ... with the U.S. Bankruptcy Court for the Southern District ... Reduction Act reimbursement cuts took effect on,January 1, 2007, ... to its secured lenders., OMI operates 21 free ...
... will respond best to interferon beta treatments , WEDNESDAY, ... why some multiple sclerosis (MS) patients respond to treatment ... with 206 southern European patients with relapsing-remitting MS, the ... the DNA of patients whose symptoms were reduced by ...
... The School of Dentistry at LSU Health Sciences Center ... dental institution recipient of the William J. Gies Award ... the ADEAGies Foundation at a black-tie celebration on March ... Education Association (ADEA) Annual Session at the Hilton Anatole ...
Cached Medicine News:Health News:Millennium Enters Into $600,000 Product Development Agreement to Fund Product Development for the $20,000,000 Purchase Agreement with Provider Services, Inc. 2Health News:STERIS Corporation Announces Date of Fiscal 2008 Third Quarter Earnings Release and Conference Call 2Health News:STERIS Corporation Announces Date of Fiscal 2008 Third Quarter Earnings Release and Conference Call 3Health News:OMI Medical Imaging, Inc. and Affiliated Companies File Chapter 11 Reorganization 2Health News:DNA Analysis Could Help Customize Treatments for MS 2Health News:LSUHSC dental school to be awarded top national honor 2
Fine & Medium Tapers....
Contour Design Eyelid Implants....
For Frontalis Suspension in patients with significant ptosis and poor levator function....
Bioceramic orbital implants insert easily into orbital socket and will not cling to surrounding tissue. Improved interconnectivity between pores enhances vascularization. Implants may be easily drill...
Medicine Products: